Drug Interactions between Biktarvy and famotidine
This report displays the potential drug interactions for the following 2 drugs:
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)
- famotidine
Interactions between your drugs
No interactions were found between Biktarvy and famotidine. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Biktarvy
A total of 444 drugs are known to interact with Biktarvy.
- Biktarvy is in the drug class antiviral combinations.
- Biktarvy is used to treat HIV Infection.
famotidine
A total of 313 drugs are known to interact with famotidine.
- Famotidine is in the drug class H2 antagonists.
-
Famotidine is used to treat the following conditions:
- Allergic Urticaria (off-label)
- Cutaneous Mastocytosis
- Duodenal Ulcer
- Duodenal Ulcer Prophylaxis
- Erosive Esophagitis
- GERD
- Hiatal Hernia (off-label)
- Indigestion
- Laryngopharyngeal Reflux (off-label)
- Pathological Hypersecretory Conditions
- Peptic Ulcer
- Stomach Ulcer
- Upper GI Hemorrhage
- Urticaria (off-label)
- Zollinger-Ellison Syndrome
Drug and food interactions
tenofovir food
Applies to: Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)
Food enhances the oral absorption and bioavailability of tenofovir, the active entity of tenofovir disoproxil fumarate. According to the product labeling, administration of the drug following a high-fat meal increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of tenofovir by approximately 14% and 40%, respectively, compared to administration in the fasting state. However, administration with a light meal did not significantly affect the pharmacokinetics of tenofovir compared to administration in the fasting state. Food delays the time to reach tenofovir Cmax by approximately 1 hour. Tenofovir disoproxil fumarate may be administered without regard to meals.
References (1)
- (2001) "Product Information. Viread (tenofovir)." Gilead Sciences
famotidine food
Applies to: famotidine
H2 antagonists may reduce the clearance of nicotine. Cimetidine, 600 mg given twice a day for two days, reduced clearance of an intravenous nicotine dose by 30%. Ranitidine, 300 mg given twice a day for two days, reduced clearance by 10%. The clinical significance of this interaction is not known. Patients should be monitored for increased nicotine effects when using the patches or gum for smoking cessation and dosage adjustments should be made as appropriate.
References (1)
- Bendayan R, Sullivan JT, Shaw C, Frecker RC, Sellers EM (1990) "Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans." Eur J Clin Pharmacol, 38, p. 165-9
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.